Tags : Urs Schenker

Corporate

Walder Wyss advises Pfizer on its investment in Anokion

As we have informed here last 10 November 2022, the clinical-stage biotechnology company Anokion has closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating autoimmune disease by restoring normal immune tolerance. Walder Wyss has also advised on the deal acting as […]

IPOs

Medmix launches its IPO following Spin-off from Sulzer. The advisors

Following the Spin-off, Sulzer and Medmix shares will start trading separately on the SIX Swiss Exchange.  In an offering of new shares, which took place at the same time, 7 million new shares were issued in Medmix at CHF 45 per share, raising gross proceeds of CHF 315 million from the capital increase, yielding net proceeds of approximately CHF […]

Deal & transactions

Sulzer Spins-off its Applicator Systems Division into medmix. The advisors

Sulzer, fluid engineering company specialising in pumping, agitation, mixing and separation technologies for fluids of all types, has successfully spun-off its Applicator Systems Division to the newly incorporated medmix, which shall be listed at SIX Swiss Exchange.  Following the approval of the spin-off by Sulzer’s shareholders on September 20, 2021, the book-building process for the offering of new shares of medmix has […]